Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Salvatore Perrone

Showing results (21-30 of 75) with videos related to

Pageof 8
Sort By:
The Open Ophthalmology Journal|March 26, 2016
Coats' Disease: Very Long-Term Outcome After Early Stage Conventional TreatmentSalvatore Perrone, Alberto Rossetti, Patrick Sportiello, et al.
Journal of Clinical Medicine|December 30, 2025
How to Read a Next-Generation Sequencing Report for AML and MDS? What Hematologists Need to KnowSalvatore Perrone, Cristina Tresoldi, Silvia Rigamonti, et al.
Cancers|January 11, 2024
Venetoclax: A Game Changer in the Treatment of Younger AML Patients?Matteo Molica, Salvatore Perrone, Vincenzo Federico, et al.
Cancers|June 24, 2022
CPX-351: An Old Scheme with a New Formulation in the Treatment of High-Risk AMLMatteo Molica, Salvatore Perrone, Carla Mazzone, et al.
Ejhaem|July 18, 2022
Unexpected cause of pancytopenia in a teenager with Noonan syndromeSalvatore Perrone, Natalia Cenfra, Federica Viola, et al.
Cancers|June 22, 2023
Novel Drugs and Radiotherapy in Relapsed Lymphomas: Abscopal Response and BeyondSalvatore Perrone, Paolo Lopedote, Vitaliana De Sanctis, et al.
Cancers|July 2, 2021
CD33 Expression and Gentuzumab Ozogamicin in Acute Myeloid Leukemia: Two Sides of the Same CoinMatteo Molica, Salvatore Perrone, Carla Mazzone, et al.
Mediterranean Journal of Hematology and Infectious Diseases|July 10, 2024
Is There a Better Therapeutic Time Window from Diagnosis to Treatment for Elderly Acute Myeloid Leukemia Patients Receiving Hypomethylating Agents?Matteo Molica, Luca Maurillo, Marco Rossi, et al.
Chemotherapy|March 7, 2021
Choosing Antifungals for the Midostaurin-Treated Patient: Does CYP3A4 Outweigh Recommendations? A Brief Insight from Real LifePierantonio Menna, Emanuela Salvatorelli, Maria Ilaria Del Principe, et al.
Leukemia Research|April 1, 2016
Splenic marginal zone lymphoma: Prognostic factors, role of watch and wait policy, and other therapeutic approaches in the rituximab eraSalvatore Perrone, Gianna Maria D'Elia, Giorgia Annechini, et al.
Pageof 8

Showing results (21-30 of 75) with videos related to

Sort By:
Pageof 8
The Open Ophthalmology Journal|March 26, 2016
Coats' Disease: Very Long-Term Outcome After Early Stage Conventional TreatmentSalvatore Perrone, Alberto Rossetti, Patrick Sportiello, et al.
Journal of Clinical Medicine|December 30, 2025
How to Read a Next-Generation Sequencing Report for AML and MDS? What Hematologists Need to KnowSalvatore Perrone, Cristina Tresoldi, Silvia Rigamonti, et al.
Cancers|January 11, 2024
Venetoclax: A Game Changer in the Treatment of Younger AML Patients?Matteo Molica, Salvatore Perrone, Vincenzo Federico, et al.
Cancers|June 24, 2022
CPX-351: An Old Scheme with a New Formulation in the Treatment of High-Risk AMLMatteo Molica, Salvatore Perrone, Carla Mazzone, et al.
Ejhaem|July 18, 2022
Unexpected cause of pancytopenia in a teenager with Noonan syndromeSalvatore Perrone, Natalia Cenfra, Federica Viola, et al.
Cancers|June 22, 2023
Novel Drugs and Radiotherapy in Relapsed Lymphomas: Abscopal Response and BeyondSalvatore Perrone, Paolo Lopedote, Vitaliana De Sanctis, et al.
Cancers|July 2, 2021
CD33 Expression and Gentuzumab Ozogamicin in Acute Myeloid Leukemia: Two Sides of the Same CoinMatteo Molica, Salvatore Perrone, Carla Mazzone, et al.
Mediterranean Journal of Hematology and Infectious Diseases|July 10, 2024
Is There a Better Therapeutic Time Window from Diagnosis to Treatment for Elderly Acute Myeloid Leukemia Patients Receiving Hypomethylating Agents?Matteo Molica, Luca Maurillo, Marco Rossi, et al.
Chemotherapy|March 7, 2021
Choosing Antifungals for the Midostaurin-Treated Patient: Does CYP3A4 Outweigh Recommendations? A Brief Insight from Real LifePierantonio Menna, Emanuela Salvatorelli, Maria Ilaria Del Principe, et al.
Leukemia Research|April 1, 2016
Splenic marginal zone lymphoma: Prognostic factors, role of watch and wait policy, and other therapeutic approaches in the rituximab eraSalvatore Perrone, Gianna Maria D'Elia, Giorgia Annechini, et al.
Pageof 8